Astellas Pharma (ALPMY.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec17

Astellas and Pfizer Announce Positive Results from EV-304 Trial

11:47

Dec1

AstraZeneca Announces EMA Validates PADCEV Combination Therapy Application

01:42

Oct31

Astellas Pharma (ADR) Soars in Net Profit by 101% in First Half

00:17

Oct30

Astellas Pharma released FY2026 Semi-Annual Earnings on October 30 After-Market (EST), Actual Revenue: USD 7.023 B (Forecast: USD 6.36 B), Actual EPS: USD 0.5602

23:00

Astellas Pharma released FY2026 Q2 earnings on October 30 After-Market EST, actual revenue USD 3.528 B (forecast USD 3.232 B), actual EPS USD 0.2964

23:00

Astellas Pharma Raises FY2025 Profit Guidance

11:27

Schedules & Filings

Schedules

Filings

Oct30

Earning Release(EST)

FY2026 Q2 Earning Release (USD) Revenue 3.528 B, Net Income 532.95 M, EPS 0.2964

Sep30

Distribution Plan(EST)

Cash dividend 0.2698 USD

Distribution Plan(EST)

Cash dividend 0.2698 USD

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change